Jack L. Erion

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3K citations · Full text

[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients

Dik J. Kwekkeboom, Willem H. Bakker, P.P.M. Kooij et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2001 · 468 citations

Clinical Translation, Medicine, Pathology +2

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

Dik J. Kwekkeboom, Willem H. Bakker, Boen L.R. Kam et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 418 citations · Full text

Surgical Oncology, Pancreatic Cancer, Medicine +6

Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities

Wouter A.P. Breeman, Marion de Jong, Theo J. Visser et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2003 · 213 citations

Biochemistry, High Specific Activities, Natural Sciences +9

Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.

M. de Jong, W A Breeman, WH Bakker et al. · PubMed · 1998 · 210 citations

Engineering, Chemoprevention Strategy, In-labeled Somatostatin +21